HYDRENOL

Hydrenol was a clinical-stage biotechnology company focused on developing topical treatments for dermatological conditions, specifically hyperhidrosis (excessive sweating). The company's core asset was a proprietary topical formulation of glycopyrronium, a muscarinic antagonist designed to block the activation of sweat glands. In 2011, Hydrenol was acquired by Dermira, which advanced the lead candidate through clinical development and eventually received FDA approval for the product under the brand name Qbrexza. The company was founded by Dr. David Pariser, a world-renowned expert in the field of hyperhidrosis research and treatment. The acquisition allowed for the successful commercialization of the first topical prescription treatment for primary axillary hyperhidrosis, which is now marketed by Journey Medical Corporation.